NRIX
Nurix Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$26.80
−1.18%Margins
Gross margin
86.5%
EBITDA margin
46.0%
EBIT margin
41.3%
Net margin
42.0%
FCF margin
52.7%
30.5%
Return on equity
24.7%
Return on assets
28.0%
Return on invested capital
0.81x
Asset turnover
$379.3M
Cash from operations
$9.60
Cash per share
Margins, returns on capital and operating efficiency from the latest trailing period · Data as of Aug 1, 2026